TENLIFAST-M 500SR / 1000SR Tablets
Better Control Means Better Life
COMPOSITION:
- Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg + Metformin Hydrochloride IP 500 mg (SR)
- Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg + Metformin Hydrochloride IP 1000 mg (SR)
- Diabetes is not just high blood sugar, it means;
- Risk of stroke
- Visual disturbance
- Risk of heart disease
- High blood pressure
- Nerve damage
- Foot problem
- Possess insulinotropic & glucagonostatic effects that control blood glucose for 24 hours.
- Safe combination for patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy.
INDICATIONS:
- In patients with T2DM without increasing risk of hypoglycemia
- Diabetic patients with cardiovascular diseases
- Elderly diabetic patients
- Metformin intolerable patients
Description
Teneligliptin
- Exhibits long-lasting & more potent inhibition of the DPP-4 enzyme than sitagliptin, vildagliptin, and alogliptin.
- Ensures stabilization of glucose fluctuations throughout the day owing to its long half-life.
- Imparts sustained effects on glycemic control, thereby reducing the complications of hypoglycemia and weight gain.
- Safe for patients with renal or liver impairment.
Metformin
- Improves glucose tolerance in patients with type-2 diabetes, lowering both basal and postprandial plasma glucose.
- Positively affect lipid profiles, and improve vascular and hemodynamic indices.
Combination
- Teneligliptin when used as part of dual therapy with metformin leads to significant Glycated Haemoglobin (HbA1c) reduction of 1.07% which incidentally is slightly better compared with phase III trials conducted for the same combination in the Korean population (HbA1c reduction of 0.87% compared to baseline at 16 weeks).
- Teneligliptin as an add-on to metformin plus sulfonylurea therapy showed a significant (P-value <0.0001) reduction in HbA1c, fasting plasma glucose, and postprandial plasma glucose.
- While 43.96% of patients receiving teneligliptin + metformin and 35.03% of patients receiving teneligliptin + metformin + sulfonylurea achieved the same target.
